R.PR
REGISTERED-PRINCIPAL REGISTER
04/05/2022
Back to search
Official data from USPTO
TEON
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
04/05/2022
Trademark type
Word
Nice classes
5, 42
Filing date
10/04/2018
Registration date
04/05/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/05/2022
Last transaction
04/05/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
02/18/2022
First use in commerce
02/18/2022
Drawing code
4
Owner type
03
Owner location
Redwood City, CA
Examiner
ORNDORFF, LINDA
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Teon Therapeutics, Inc.
Representatives
Michelle D. Kahn Sheppard Mullin
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for treating cancer; pharmaceutical preparations for the treatment or prevention of dermatologicalcardiovascularhematologicalbonerespiratorycentral nervous systemendocrinologicalcirculatorygastroenterologicaldigestivehormonaldiabeticmuscularrheumaticimmune systemocular and metabolic diseases and disorders; pharmaceuticals for treating acromegalyneuroendocrine tumorsCushing's Diseasehyperinsulinismchronic pain; pharmaceutical preparations for use in immunologyoncology including immuno-oncologycardiovascular and metabolic diseasesinfectious diseases; pharmaceuticals designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseasesincluding cancerautoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivityrespiratory diseasesgastrointestinal diseasescardiovascular and metabolic diseasespathogen infectionsmusculoskeletal diseasesophthalmologic and dermatologic diseasesgenitourinary diseasesdegenerative diseasesorphan diseases; protein therapeuticspharmaceutical preparations for use in immunology including rheumatologyoncology including immuno-oncologypulmonologygastroenterologyendocrinologydermatologyurologygynecology including fertilityinfectiology including virologyophthalmologyhepatologyneurologygeriatrics; protein therapeuticsproteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseasesincluding cancer and autoimmune disorderscytokinesinterferonstumor cell targeting and cytolytic agentstolerogenic and antiallergic factorsgrowth and differentiation factorshormonesreplacement enzymescoagulation factorslipid binding proteinsprotein factors for manufacturing of adoptive cell therapy productsanti-infectivespain killerstissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areasprotein arrays for medical diagnosis purposes; pharmaceutical preparationssynthetic proteins for use in immunology including rheumatologyoncology including immuno-oncologypulmonologygastroenterologyendocrinologydermatologyurologygynecology including fertilityinfectiology including virologyophthalmologyhepatologyneurologygeriatrics
Class 42
Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of treating cancer; medical research for use in oncology; pharmaceutical research for treating acromegalyneuroendocrine tumorsCushing's Diseasehyperinsulinismchronic pain; medical research for the treatment or prevention of dermatologicalcardiovascularhematologicalbonerespiratorycentral nervous systemendocrinologicalcirculatorygastroenterologicaldigestivehormonaldiabeticmuscularrheumaticimmune systemocular and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific researchconducting clinical trials for others; laboratory research services relating to pharmaceuticals; pharmaceutical research in the field of protein therapeutics; pharmaceutical research in the fields of immunology including rheumatologyoncology including immuno-oncologypulmonologygastroenterologyendocrinologydermatologyurologygynecology including fertilityinfectiology including virologyophthalmologyhepatologyneurologygeriatricslaboratory medicineclinical diagnosticsgenetics and phenomicspathology and forensicsproteomicsveterinary medicine and diagnosticsbasic research tools; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research using a semi-synthetic organism for use in drug development; pharmaceutical researchresearch relating to synthetic proteins incorporating one or more non-natural amino acids for improving pharmacological properties; pharmaceutical researchresearch relating to synthetic proteins for use in connection with a wide variety of therapeutic agents
Publications
History of USPTO decisions and trademark events.
38 publications found
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02/26/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02/25/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
02/22/2022
IUAF
USE AMENDMENT FILED
02/18/2022
EISU
TEAS STATEMENT OF USE RECEIVED
02/18/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/23/2021
EX5G
SOU EXTENSION 5 GRANTED
10/22/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/22/2021
EXT5
SOU EXTENSION 5 FILED
10/14/2021
EEXT
SOU TEAS EXTENSION RECEIVED
10/14/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/20/2021
EX4G
SOU EXTENSION 4 GRANTED
04/16/2021
EXT4
SOU EXTENSION 4 FILED
04/16/2021
EEXT
SOU TEAS EXTENSION RECEIVED
04/16/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/05/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/05/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/05/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/26/2020
EX3G
SOU EXTENSION 3 GRANTED
09/24/2020
EXT3
SOU EXTENSION 3 FILED
09/24/2020
EEXT
SOU TEAS EXTENSION RECEIVED
09/24/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/22/2020
EX2G
SOU EXTENSION 2 GRANTED
04/20/2020
EXT2
SOU EXTENSION 2 FILED
04/20/2020
EEXT
SOU TEAS EXTENSION RECEIVED
04/20/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/01/2019
EX1G
SOU EXTENSION 1 GRANTED
09/27/2019
EXT1
SOU EXTENSION 1 FILED
09/27/2019
EEXT
SOU TEAS EXTENSION RECEIVED
09/27/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/23/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/26/2019
PUBO
PUBLISHED FOR OPPOSITION
02/26/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/06/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/17/2019
DOCK
ASSIGNED TO EXAMINER
01/16/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/13/2018
NWAP
NEW APPLICATION ENTERED
10/08/2018
Continuous trademark protection
Get notified about every new filing that threatens TEON or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.